The ELAVL2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ELAVL2 gene. This heterogeneous pool of HeLa cells contains diverse loss-of-function mutations, offering a model for studying ELAVL2-dependent processes without clonal selection biases. The polyclonal format is advantageous for investigating post-transcriptional regulation in a context that maintains population-level genetic diversity.
The HeLa host line, an immortalized cervical adenocarcinoma cell line established in 1951, is widely used for gene-editing studies. Its genome harbors HPV18 sequences that inactivate p53 and Rb via E6 and E7 oncoproteins, providing a cellular environment with compromised tumor suppressor pathways. This background is particularly relevant for research on cancer biology and stress responses.
ELAVL2 is an RNA-binding protein that recognizes AU-rich elements (AREs) in 3?? UTRs, stabilizing and enhancing translation of bound mRNAs. It governs the expression of neuronal and stress-responsive genes, including FOS, JUN, GAP43, BCL2, and BDNF. Its activity is regulated by upstream signals like neurotrophin signaling and transcription factors NEUROD1 and ASCL1, and it collaborates with ELAVL1, ELAVL3, ELAVL4, PABPC1, and AGO2 in multiprotein regulatory complexes.
In HeLa cells, ELAVL2 knockout decouples its RNA-regulatory functions from neuronal context, enabling dissection of ARE-mediated mechanisms in a carcinoma background. This is salient because ELAV proteins are frequently aberrantly expressed in cancers, and HeLa??s p53/Rb deficiency may intersect with ELAVL2-regulated pathways controlling cell survival and proliferation. The model thus provides insights into post-transcriptional contributions to malignancy.
Researchers can use these cells for luciferase reporter assays tracking ARE-dependent mRNA stability, RIP to identify ELAVL2 targets, and RT-qPCR, RNA-seq, or western blot to profile molecular changes. Flow cytometry facilitates population-level phenotypic analyses. The knockout is applicable to drug discovery efforts aimed at modulating mRNA turnover. For additional details, contact Ascent Research.
